New Biomarkers for Utrophin Protein Levels Likely to Aid DMD Therapy Now in Clinical Testing - Muscular Dystrophy News: "Summit Therapeutics plc announced the publication of a study into new imaging techniques that appear to reliably and reproducibly measure utrophin protein levels and muscle fiber regeneration in muscle biopsies in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) patients.
The study is important to the company because one of its lead products, now in clinical testing, is SMT C1100, a small molecule utrophin modulator that has been shown in a mice model of DMD to increase utrophin in skeletal and diaphragm muscle, leading to a significant decrease in disease pathology and an improved functional benefit. Utrophin up-regulation is considered a possible therapeutic option for all DMD patients, regardless of their underlying dystrophin mutation."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment